is yerba mate a glp-1 agonist Yalei Drink Mix–Support Dual Action Craving & Metabolism | Berberine, Cinnamon .Chromium, 5-HTP, & Magnesium | Supports Blood Sugar & Gut Health Unlocking the Health Benefits of

Patients may privately obtain these medications, so its important to enquire non-judgmentally (e.g., To ensure safe prescribing, are you taking any weight loss medications you buy online?)

Declines were even more pronounced among households with GLP-1 weight loss users, who decreased food spending six times faster than non-GLP-1 households (-3%)

1,2 More importantly, they reduce life expectancy by 814 years on average, 2,3 often due to cardiometabolic comorbidities

According to the data administering 500 mg/kg of this substance in rats has shown an antidiabetic effect, attributable to berberine, which enhances insulin production and stimulates glycolysis

Although much of the hair loss being reported after starting GLP-1 medications could be temporary telogen effluvium related to rapid weight loss or nutritional stress, he believes it is entirely plausible that in those genetically predisposed to androgenetic alopecia, [GLP-1s] may be triggering its early onset. Nusbaum, of the Miami Hair Institute, said he has started to see several patients with underlying androgenetic alopecia, which is male- or female-pattern hair loss, where that underlying condition is being exacerbated by the use of these medications. Androgenetic alopecia has a distinct pattern

Cagrilintide development and structure What cagrilintide is: Synthetic long-acting amylin analog Modified 37-amino acid sequence Developed by Novo Nordisk Designed specifically for obesity treatment Based on natural amylin but optimized Key structural modifications: Amino acid substitutions for stability Prevented amyloid aggregation (major improvement) Extended half-life to ~7 days (vs minutes for natural amylin) Maintained receptor binding and activity Better pharmacokinetic profile Development timeline: Early 2010s: Initial development 2019-2020: Phase 2 trials (OASIS) 2021-2023: Phase 3 trials (REDEFINE as CagriSema) 2024-2025: FDA submission expected Likely approval 2025-2026 Why cagrilintide is breakthrough: First truly long-acting amylin agonist Weekly dosing (vs pramlintide 2-3x daily) Designed for weight loss (not diabetes adaptation) Proven synergy with semaglutide (CagriSema) Approaching availability Cagrilintide weight loss results Monotherapy clinical data (OASIS trials): Duration: 26-68 weeks Dose: 2.4mg weekly (standard) Average weight loss: 10-12% Some participants: 15%+ loss Well-tolerated at therapeutic dose Weight loss by dose: 0.6mg weekly: ~6% weight loss 1.2mg weekly: ~8% weight loss 2.4mg weekly: ~10% weight loss 4.5mg weekly: ~12% weight loss (higher side effects) CagriSema combination (cagrilintide + semaglutide): Both at 2.4mg weekly Average weight loss: 15.6% (REDEFINE-1) Excellent responders: 20-25% 50% more than semaglutide alone Game-changing results Real-world expectations: See our comprehensive cagrilintide weight loss guide